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Background and Purpose—Risk of tumorigenesis is a major obstacle to human embryonic and induced pluripotent stem
cell therapy. Likely linked to the stage of differentiation of the cells at the time of implantation, formation of
teratoma/tumors can also be influenced by factors released by the host tissue. We have analyzed the relative effects of
the stage of differentiation and the postischemic environment on the formation of adverse structures by transplanted
human embryonic stem cell-derived neural progenitors.
Methods—Four differentiation stages were identified on the basis of quantitative polymerase chain reaction expression of
pluripotency, proliferation, and differentiation markers. Neural progenitors were transplanted at these 4 stages into rats
with no, small, or large middle cerebral artery occlusion lesions. The fate of each transplant was compared with their
pretransplantation status 1 to 4 months posttransplantation.
Results—The influence of the postischemic environment was limited to graft survival and occurrence of nonneuroecto-
dermal structures after transplantation of very immature neural progenitors. Both effects were lost with differentiation.
We identified a particular stage of differentiation characterized in vitro by a rebound of proliferative activity that
produced highly proliferative grafts susceptible to threaten surrounding host tissues.
Conclusion—The effects of the ischemic environment on the formation of teratoma by transplanted human embryonic stem
cell-derived neural progenitors are limited to early differentiation stages that will likely not be used for stem cell therapy.
In contrast, hyperproliferation observed at later stages of differentiation corresponds to an intrinsic activity that should
be monitored to avoid tumorigenesis. (Stroke. 2010;41:153-159.)
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The potential of stem cell transplantation for the treatmentof acute brain lesions has been highlighted by a number
of experimental results. Among available cell sources, em-
bryonic stem cells (ESCs) offer advantages related to their
main attributes, pluripotency, and self-renewal. However,
both properties come with major drawbacks that will also
apply to induced pluripotent stem cells that express ESC-like
characteristics.1
Pluripotency can generate teratoma, a tissue characterized
by the presence of mature derivatives of at least 2 of the 3
germ layers.2 Occurrence of teratoma was reported indepen-
dently of the origin of the ESC, that is, mouse,3,4 nonhuman
primate5 or human,6,7 and with allografts8 or xenografts,9,10
although a higher incidence was reported in allograft situa-
tions.8 Although the question has been controversial,11 ESCs
may generate nonmalignant teratoma rather than malignant
teratocarcinoma12 that is characterized by the presence of
cells that indefinitely maintain pluripotency. To avoid tera-
toma, much effort has been devoted to the elaboration of
differentiation protocols that allow maximal homogeneity of
the transplant6 or to cell sorting before transplantation to
eliminate nonneural progenitors.13–15
A more recent series of studies have reported a different
risk of tumor formation after transplantation of ESC deriva-
tives into the brain,6,15,16 which corresponds to maintained
proliferation of differentiated progenitors. This process, also
referred to as “graft overgrowth,” is characterized by the
exclusive presence of neural cells, therefore excluding the
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classification as teratoma, that may provoke compression and
disruption of host brain structures.
A major issue raised by those results is the relative role of
intrinsic and environmental factors in the development of
adverse structures in the host brain. It is unclear whether this
development is only linked to the persistence of poorly
differentiated cells into the graft or whether, in addition,
dedifferentiating/proliferative signals may be released by the
lesioned brain. Acute stroke involves strong inflammatory
and glial reactions with elevated contents of key cytokines in
human ESC (hESC) amplification and differentiation such as
basic fibroblast growth factor17 and brain-derived neurotro-
phic factor.18 The possibility that these factors induce a
reversal of the commitment of ESC derivatives and/or favor
cell proliferation is, therefore, of particular importance for
cell therapy to patients with stroke.
We have analyzed the influence of the ischemic environ-
ment on the formation of teratoma/tumors by transplanted
hESC-derived neural progenitors (NPGs). Human ESCs dif-
ferentiated toward the neural lineage with limited instructive
cues were transplanted into brains with no, small, or large
middle cerebral artery occlusion lesions. We show that the
postischemic environment influences the formation of tera-
toma formed by NPG in their early stages of differentiation.
We also reveal that tumorigenesis by differentiated NPG
corresponds to a peak of proliferative activity that can be
monitored in vitro and is independent of the environment.
Materials and Methods
Cell Culture
Human ESCs (SA-001, XY, Cellartis AB) were differentiated for 86
days in vitro (div) on MS5 feeders, then polyornithin/laminin16 with
a medium restricted to N2 supplement (Invitrogen), 20 ng/mL
brain-derived neurotrophic factor (R&D Systems), and 10 ng/mL
basic fibroblast growth factor (Invitrogen). Cells were passaged at
the time of seeding on polyornithin/laminin-coated dishes (20-div) at
30-, 45-div, and between 60- and 80-div corresponding to 80%
confluence.
Transcriptional Analysis
Total RNA was isolated with the RNeasy Mini Kit (Qiagen). One
microgram mRNA was reverse-transcribed with SuperScript II
(Invitrogen). Real-time quantitative polymerase chain reaction was
performed in triplicates with the Power SYBR Green PCR Mix
(Applied Biosystems) and a Chromo 4TM Real-Time amplifier
(Bio-Rad). The amplification efficiency of each primer pair (Table)
was determined with a standard curve from fetal brain cDNA
(Clontech). Quantification was performed at a threshold detection
line (Ct value). The Ct of each target gene was normalized against
that of the 18S housekeeping gene. Gene relative expression levels
were determined with the 2-Ct method with hESC cDNA as a
calibrator. Data are expressed as meanSEM.
Ischemia and Transplantation
All animal experimentation was performed on compliance of the
European ethical guidelines (86/609/EEC). A total of 192 adult (250 g)
male Sprague-Dawley rats (Charles River, Larbresle cedex, France)
were used in 2 separate experiments (n102 and n90, respec-
tively). In each experiment, animals were randomly allocated to 3
groups to receive a transient middle cerebral artery occlusion19 with
isoflurane (Centravet) anesthesia (Figure 1). In one third of the animals,
the filament was immediately removed (sham group). The striatal lesion
group (STR) received a 90-minute occlusion, and the STR cortical
lesion group (STR-Cx) a 2-hour occlusion. Animals were followed for
body weight and potential postoperative complications during 48 hours
and were transplanted 7 days postsurgery.
NPGs were transplanted weekly along their differentiation process
from 21- to 49-div (n6 for each time point and each lesion group)
and then at 86-div (n6 for each lesion group). In the first
experiment, 2 additional animals in each lesion group were trans-
planted with either hyperproliferative NPG (or late-NPG; Figure 2;
n6 in total) into the lateral ventricle or with detaching embryoid
body-like structures present in early NPG cultures (Figure 3A; n6
in total).
Animals received a daily administration of cyclosporin A (8 mg/kg,
intraperitoneally, Sandimmun; Novartis), azathioprine (2 mg/kg, subcu-
taneous, Immurel; GlaxoSmithKline), and methylprednisolone (2
mg/kg, intraperitoneal, Solu-Medrol; Pfizer) starting the day before
transplantation and for the whole duration of the experiment. Four
animals died after transient middle cerebral artery occlusion surgery
(one in the sham and 3 in the STRCx group) and 2 additional
animals died after transplantation (one in the sham and one in the
STR group).
Table. List of Quantitative Polymerase Chain Reaction Primers
Ki67 Proliferation tgatggttgaggtcgttccttg tcctttggtgggcacctaagac 157
PCNA Proliferation tccactctcttcaacggtgaca tcgatcttgggagccaagtagta 90
Nanog ESC caaaggcaaacaacccactt tctgctggaggctgaggtat 158
Oct4 ESC cttgctgcagaagtgggtggaggaa ctgcagtgtgggtttcgggca 168
Sox2 ESC, neurogenesis acagcaaatgacagctgcaaa tcggcatcgcggttttt 67
Pax6 Neural progenitor gccagcaacacacctagtca tgtgagggctgtgtctgttc 138
Sox1 Neural progenitor atgcaccgctacgacatgg ctcatgtagccctgcgagttg 65
Musashi Neuronal precursor gccaagatggtgactcg atggcgtcgtccaccttc 111
Figure 1. Representative examples of the 3 types of environ-
ment. A, Sham: no lesion. B, STR: loss of the lateral striatal
quadrant. C, STR-Cx: loss of the whole middle cerebral artery
territory. Volume reconstruction from 12 cresyl violet sections at
180- interval. Percentages indicate the volume of the ipsilateral
hemisphere (Hemisph.) or striatum to the contralateral
(contralat.) tissue.
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MRI was performed using a 4.7-T Bruker spectrometer equipped
with a custom made surface coil. A T2-weighted turbospin echo
sequence RARE (repetition time TR3000 ms, effective echo time
TE36.0 ms, turbo factor8, number of acquisitions AC8, field of
view3.5 cm, matrix 256256, slice thickness 0.85 mm, acquisition
time 9 minutes 36 seconds) was used, providing quality transversal/
coronal anatomic images.
Tissue Processing
Rats were terminally anesthetized after 1 or 4 months with 100
mg/kg sodium pentobarbital (Ceva) and were perfused with
phosphate-buffered 4% paraformaldehyde. Three rats in the STR
group transplanted with 86-div cells were perfused after 3 months.
Cryostat-cut 30-m-thick brain sections were stained with Cresyl
violet for reconstruction of lesion volumes (Free-D software, Amib,
France; Figure 1) or processed for immunohistochemistry. Antibod-
ies were rabbit polyclonal to glial fibrillary acidic protein, nestin
(Chemicon), doublecortin (Abcam), human DARPP-32 (Santa-Cruz
Biotechnology), Pax6, and -tubulin III (Covance); mouse IgG to
human nuclei (Chemicon), Oct4 (Santa Cruz Biotechnology),
cytokeratin-14 (Chemicon), rat tyrosine hydroxylase, MAP2
(Sigma); and mouse IgM to Ki67 (Sigma). Secondary antibodies
were Alexa488- and Alexa555-labeled (Molecular Probes; 1:1000)
and 4,6-diamidino-2-phenylindole was used to visualize nuclei.
Controls were performed with the corresponding isotypes. Observa-
tions were performed on a Zeiss Axioplan microscope with ImageJ
(http://rsb.info.nih.gov/ij) for image analysis.
Results
Pretransplantation Differentiation Profile
The differentiation profile of SA-001 hESC was divided into
4 stages on the basis of the expression of pluripotency, prolif-
eration, and maturation markers (Figure 2). As compared with
levels recorded in undifferentiated hESC, early NPG (21- to
28-div) still contained high levels of Oct4 (34.6%6.6%),
Nanog (37.8%6.1%), and Sox2 (23.3%4.5%) and of the
proliferation markers Ki67 (93.8%9.2%) and proliferating
cell nuclear antigen (198.62.5%). Mid-NPG (35-div) no
longer expressed ESC markers (Oct4: 0.6%0.3%; Nanog:
Figure 2. Four differentiation stages
(early, mid, and late NPG and NP) are
defined by expression of pluripotency,
proliferation, and differentiation markers
illustrated by phase-contrast pictures
(early NPGs are shown in Figure 3). FB,
fetal brain. Data are expressed as per-
centage of mRNA levels in hESC.
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2.7%0.7%; Sox1: 1.8%0.1%) and showed decreased levels
of Ki67 (49.85.2%) and proliferating cell nuclear antigen
(133.547.7%). Keeping hESC levels as a baseline, late NPGs
(42- to 49-div) were characterized by strong expression of the
neural markers Pax6 (761036245%), appearance of MAP2
(1286%303%), Sox1 (10 954%872%) and Musashi
(5858%36%) and strong Ki67 (130.3%36%) and prolif-
erating cell nuclear antigen (145%11%) expression in
correlation with a high proliferative activity of rosettes in
vitro. The fourth stage (neuronal precursors [NPs]) had Ki67
(57.8%39.7%) and proliferating cell nuclear antigen
(32.4%1.5%) levels similar to mid-NPG and neuronal
marker levels close to fetal brain.
Graft Survival
Overall graft survival was of 77.4%10.6%. Large lesions
significantly promoted the survival of transplanted early NPG
(83.3% versus 33.5% in sham; 2 test, P0.0005). Signifi-
cance was lost with differentiation (average 95.4%7.9%
survival; 2 test, P0.72).
Teratoma Formation
Considering the lack of consensus in the literature about the
terminology of ESC-derived structures after transplantation,
we have followed Nature Biotechnology12 recommendations.
No teratocarcinomas were observed after transplantation of
NPG at any differentiation stage. In contrast, invasive tera-
tomas with mature tissues from the 3 germ layers consistently
formed after transplantation of the embryoid body-like struc-
tures present in early NPG cultures (Figure 3; 6 of 6 animals).
They could be identified with T2 MRI by their nonhomog-
enous aspect. They ranged from 3 to 6 mm in diameter and
occurred independently of the lesion (Figure 3C–F). Embry-
oid body-like structures are eliminated during the second
passage (30-div) and were no longer present in mid-NPG.
Teratoma (“benign tumors composed of somatic tissues”)12
containing mesoderm-derived mature cartilage (Figure 4A) or
ectoderm-derived cystic cavities (Figure 4B) or keratinocytes
(Figure 4C) were observed after transplantation of early NPG
in addition to neural cells (Figure 4D–E). Nonneuroectoder-
mal structures were more frequent in animals with STR-Cx
lesions (100%; Fisher test, P0.0023 compared with sham)
than in STR (66.7%; Fisher test, P0.07) and sham (60%).
Only neuronal cell types were observed after 1 month in grafts
from mid-NPG (Figure 4F–I), late-NPG (Figure 4J–M), and NP
(Figure 4N–Q).
Tumor Formation
A main characteristic of late NPG-derived grafts was the
multiplication of rosettes containing numerous Ki67-labeled
cells (Figure 4J–K). Rosette-rich grafts developed indepen-
dently of the lesion presence or size, including after trans-
plantation into the lateral ventricle (Figure 4M). After 1
month, they ranged in size from 1 (n7) to 3 mm (n1,
lateral ventricle group). Although no compressions of sur-
rounding structures were observed in late NPG-grafted ani-
mals, examples of compressive tumors have been described
after longer posttransplantation delays.7,14 Tumors were com-
posed only of neural cells.
Differentiation and Integration Into the
Host Parenchyma
In agreement with their pretransplantation commitment, mid-
NPG grafts contained doublecortin-migrating neuroblasts
(Figure 4H) and MAP2 neurons sending long processes
through the corpus callosum (Figure 4I). Host-derived glial
fibrillary acidic protein astrocytes were seen overlying the
grafts (Figure 4G). Interestingly, host astrocytes would not
invade nonneural and nondifferentiated (Figure 4L) struc-
tures, indicating recognition of the graft content. Glial fibril-
lary acidic protein-positive astrocytes of graft origin were
present only in the 4-month-old grafts derived from NP
(Figure 4N) in parallel with DARPP-32 (Figure 4O–P), a
phosphoprotein enriched in the dopaminoceptive striatal neu-
rons destroyed by ischemia, reflecting terminal differentiation
of a subset of neurons. DARPP-32 neurons represented 6% in
average of grafted cells and formed patches that correlated
with a dense tyrosine hydroxylase innervation from the host
(Figure 4Q).
Discussion
The main result of this study is the identification of 2 different
origins for adverse events after transplantation of hESC-
derived NPG. The first mechanism, teratoma formation, depends
Figure 3. Teratomas (B) developed from embryoid body-like
structures (arrowhead in A) present in early NPG cultures (A)
together with rosettes (black frame). MRI images show that tera-
toma of various sizes form independently of the presence (C, E)
or not (D, F) of an ischemic lesion.
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on environmental cues because it increased after grafting into the
postischemic parenchyma. The second mechanism, graft over-
growth, is independent on the environment and relates to the
existence of a peak of intrinsic proliferative activity that occurs
at a later stage of differentiation.
Ischemia Influences Teratoma/Hyperproliferation
Formation by Early NPG
The observed impact of the postischemic environment on
teratoma formation may relate to the strong expression of
antiapoptotic factors after stroke, which can promote both
graft survival and teratoma formation,20 or of factors known
for their role in self-renewal, like basic fibroblast growth
factor.17 As indicated by the quantitative polymerase chain
reaction analysis, early NPG grafts still contained high levels
of markers of pluripotency and proliferation. Rather than a
dedifferentiating effect of the lesion,8 this suggests a contam-
ination of the grafts by cells with limited commitment that
responded to environmental cues present in the postischemic
brain as they did in vitro before transplantation. An increased
occurrence of teratomas has been reported in allograft versus
xenograft of undifferentiated or lightly differentiated cells.10
Although poorly differentiated progenitors must definitely be
excluded from stem cell therapy products, preclinical studies
Figure 4. Fate of transplanted NPG and NP. A–E, Early NPG develop into nonneuroectodermal structures (A, cartilage), and into mature
ectodermal (B, cystic epithelium; inset shows the alignment of single human (human nuclei, green) cells; C, cytokeratin-14 keratino-
cytes) and neural (D–E) cell types. Arrow in D indicates the border of a cystic cavity. F–I, Mid-NPG contain rosettes (nestin staining in F)
that generate large amounts of neurons (G) migrating into the host parenchyma (doublecortin staining in H) and sending processes
through corpus callosum (cc in I) and into the cortex (c). J–M, Late NPG grafts contain numerous rosettes (J, inset shows a mitosis)
with proliferative centers (K). Host astrocytes avoid rosettes (L, compare with G). Rosette-rich grafts in the lateral ventricle (M). N–Q,
Four months after transplantation, graft-derived astrocytes (N) and DARPP-32 neurons (O–P) are observed in NP-derived grafts.
DARPP-32 neurons form patches that receive host tyrosine hydroxylase afferents (Q, section adjacent to P).
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with allografts of extensively differentiated progenies are still
needed.
The ischemic parenchyma also releases a number of cytokines
and factors that have protective effects on neurons, including
vascular endothelial growth factor21 and endothelial nitric
oxide synthase22 produced by endothelial cells or glia-derived
neurotrophic factor produced by astrocytes.23 Neural progen-
itors express receptors for basic fibroblast growth factor.24
The prosurvival effect of brain lesions has been reported.25
However, it was no longer significant after differentiation
into NPs, which apparently differ from early NPG in their
sensitivity to extrinsic trophic factors or to transplantation.
In contrast with a previous report,26 transplantation into the
adult ischemic brain did not essentially modify the fate of
hESC-derived progenitors. Nonneural cell types and Oct4-
positive cells were found after transplantation of early NPG
containing high levels of Oct4 mRNA. Groups of rosettes
were observed after transplantation, including into the lateral
ventricles, of late NPG that contained highly proliferative
rosettes. The delayed apparition of NP-derived glial fibrillary
acidic protein-positive cells in the graft after transplantation
of NP was consistent with a normal neurogenesis process.
Discrepancies between the 2 studies might come from the
status of the host (neonate versus adult) or from accelerated in
vitro differentiation in a culture medium greatly enriched
compared with ours.
Overgrowth
Besides the possibility of teratoma formation, hESC-derived
grafts pose a risk for extensive graft growth that can lead to
compression and necrosis of the surrounding tissue. Over-
growths have been reported in grafts from human fetal
tissue27 and from hESC-derived rosettes.7,16,28,29 In our study,
large grafts were exclusively neural composed of rosettes that
generated impressive amounts of nestin-positive progenitors
and Tuj1-positive neurons at the expenses of the host tissue.
Overgrown grafts occurred exclusively after transplantation
of NPG that were characterized in vitro by a high proliferative
activity after the second passage. This suggests that late
NPGs constitute a particular maturation stage comparable to
one of orchestrated waves of proliferation observed during
normal central nervous system development.30
Conclusions
This study shows that hESC-derived NP develop according
to, and at the pace of, their own developmental program after
transplantation into the rodent ischemic brain. The impact of
ischemia on the formation of nonneural tissues is limited to
poorly differentiated populations that are not suitable for stem
cell therapy. In contrast, the proliferation profile must be
monitored to avoid overgrowth after transplantation. These 2
newly revealed phenomena should be taken into account in
setting up programs of cell therapy for stroke and, more
generally, for brain disorders.
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